Botulinum Toxin Carrier Formulation for Extended Upper Limb Spasticity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for upper limb spasticity using botulinum toxin require frequent injections due to a short duration of effect, typically lasting only 4-12 weeks, necessitating regular neurological interventions.
Innovation Solution
A method involving the use of injectable compositions comprising botulinum toxin non-covalently associated with a positively charged carrier, such as a positively charged polylysine backbone, to enhance toxin diffusion and stability, providing a therapeutic effect lasting at least 16 weeks to 36 weeks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If botulinum toxin is administered through intramuscular injections for upper limb spasticity, then muscle spasticity is reduced and passive function is improved, but the treatment duration is limited to 12 weeks requiring frequent re-injection
Solution Approach 1:
The patent combines botulinum toxin with a carrier protein (such as albumin or immunoglobulin) to create a composite injectable formulation. This carrier protein complex extends the duration of action of the botulinum toxin, allowing treatment effects to last beyond the typical 12-week limit while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent modifies the pharmacokinetic parameters of botulinum toxin by changing its molecular environment through carrier protein association. This alters the degradation rate and distribution characteristics, thereby extending the duration of action without compromising the toxin's ability to inhibit acetylcholine release at the neuromuscular junction.
2Adaptability or versatility
If multiple muscles are injected separately to treat spasticity, then comprehensive treatment coverage is achieved, but the total quantity of toxin that can be injected is limited by diffusion characteristics
Solution Approach 1:
The carrier protein acts as an intermediary that modifies the diffusion characteristics of botulinum toxin in the muscle tissue. This intermediary substance enhances the distribution and penetration of the toxin, allowing safer and more effective injection of higher total quantities across multiple muscle groups without excessive local accumulation.
3Reliability
If regular neurological interventions are performed to maintain treatment effect, then spasticity management is sustained, but treatment frequency and caregiver burden increase
Solution Approach 1:
By formulating botulinum toxin as a composite with carrier proteins, the patent achieves sustained treatment effects that last longer than the standard 12 weeks. This reduces the frequency of required neurological interventions and extends the time between treatments, thereby reducing caregiver burden and time loss.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method extends the duration of treatment for upper limb spasticity, reducing the frequency of injections and improving patient convenience and well-being by maintaining therapeutic effects for an extended period.
Implementation Method 1
a botulinum toxin component and a positively charged carrier; and a pharmaceutically acceptable diluent for injection; wherein the botulinum toxin is administered to the individual in an amount from about 250 U to about 1000 U; wherein the positively charged carrier is non-covalently associated with the botulinum toxin component
Implementation Method 2
enhance toxin diffusion and stability, providing a therapeutic effect lasting at least 16 weeks to 36 weeks
Data Source
AI summary
This invention provides compostions for and methods of treating upper limb spasticity (ULS) with novel injectable compositions comprising botulinum toxin that may be administered to a subject suffering therefrom. The injectable compositions and methods in which these compositions are used provide novel and advantageous treatments which result in long duration of effect, for example, a duration of effect for 16 weeks and longer, such as 20 weeks, 24 weeks, 28 weeks, 32 weeks, or 36 weeks.